| Filed On | Filing |
|---|---|
| 03 Nov 2025 |
8-K/A: Entry into a Material Definitive Agreement
CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREAT... |
| 28 Jun 2013 |
8-K/A: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On October 15, 2008, Isis Pharmaceuticals, Inc. (“Isis”) and RBS Asset Finance, Inc. (“RBS”) originally entered into a Loan Agreement related to an equipment financing. On June 27, 2012 Isis and RBS amended the Loan Agreement to extend t... |
| 28 Jun 2012 |
8-K/A: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On October 15, 2008, Isis Pharmaceuticals, Inc. (“Isis”) and RBS Asset Finance, Inc. (“RBS”) originally entered into a Loan Agreement related to an equipment financing. On June 27, 2012 Isis and RBS amended the Loan Agreement to extend t... |
| 20 Jun 2011 |
8-K/A: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On October 15, 2008, Isis Pharmaceuticals, Inc. (“Isis”) and RBS Asset Finance, Inc. (“RBS”) originally entered into a Loan Agreement related to an equipment financing. On November 15, 2010 Isis and RBS amended the Loan Agreement to exte... |
| 23 Jun 2010 |
8-K/A: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On June 21, 2010, Isis Pharmaceuticals, Inc. (“Isis”) drew approximately $3.1 million in additional principal under its Loan Agreement with RBS Asset Finance, Inc. (“RBS”). Isis and RBS originally entered into a Loan Agreement related to... |
| 02 Oct 2009 |
8-K/A: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On October 15, 2008, Isis Pharmaceuticals, Inc. (“Isis”) and RBS Asset Finance, Inc. (“RBS”) entered into a Loan Agreement related to an equipment financing, and on September 30, 2009 Isis and RBS amended the Loan Agreement to increase t... |
| 30 Mar 2009 |
8-K/A: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On October 15, 2008, Isis Pharmaceuticals, Inc. (“Isis”) and RBS Asset Finance, Inc. (“RBS”) entered into a Loan Agreement (the “Loan Agreement”) related to an equipment financing. Under the Loan Agreement, Isis and its subsidiaries may ... |
| 12 Jan 2009 |
8-K/A: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +1 more
On January 30, 2008, Isis Pharmaceuticals, Inc. (“Isis”) and its former subsidiary, Ibis Biosciences (“Ibis”), entered into a Strategic Alliance Master Agreement, a Call Option Agreement and an Investor Rights Agreement with Abbott Molec... |
| 17 Dec 2008 |
8-K/A: Entry into a Material Definitive Agreement
CARLSBAD, Calif. and Abbott Park, Ill., December 17, 2008 - Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Abbott (NYSE: ABT) announced today that Abbott has exercised its option to purchase the remaining equity ownership in Ibis Bioscien... |
| 06 Feb 2008 |
8-K/A: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
On January 7, 2008, Isis Pharmaceuticals, Inc. (“Isis”) and Genzyme Corporation (“Genzyme”) announced a major strategic alliance in which Genzyme will develop and commercialize mipomersen. Mipomersen, formerly ISIS 301012, is a lipid-low... |
| 07 Dec 2007 |
8-K/A: Financial Statements and Exhibits
We consent to the incorporation by reference in the Registration Statements (Form S-3 Nos. 33-55790, 33-72124, 33-75068, 33-96138, 333-71911, 333-90811, 333-38844, 333-71116, 333-71176, 333-89066, 333-89626, 333-128156, 333-130639, 333-1... |
| 02 Oct 2007 |
8-K/A: Entry into a Material Definitive Agreement
ISIS ANNOUNCES HSR APPROVAL AND CLOSURE OF ITS COLLABORATION WITH ORTHO-MCNEIL, INC. |
| 13 Nov 2006 |
8-K/A: Other Events
November 13, 2006 ISIS 301012 Phase 2 Results and Program Overview |
| 05 May 2005 |
8-K/A: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities
CARLSBAD, CA, May 5, 2005 — Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), today announced its financial results for the quarter ended March 31, 2005. The Company’s proforma loss from operations was $17.1 million for the three months ended M... |
| 01 Mar 2005 |
8-K/A: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities
Carlsbad, CA, March 1, 2005 - Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), today announced its unaudited financial results for the year ended December 31, 2004. In line with its guidance, the Company’s proforma loss from operations was $85... |
| 05 Oct 2001 |
8-K/A: Financial Statements and Exhibits
CERTIFICATE OF DESIGNATION OF THE SERIES B CONVERTIBLE PREFERRED STOCK (PAR VALUE $.001 PER SHARE) OF ISIS PHARMACEUTICALS, INC. |
| 16 Jun 1999 |
8-K/A: Financial Statements and Exhibits
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| 08 Jun 1999 |
8-K/A: Completion of Acquisition or Disposition of Assets
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Loading...